Susquehanna International Group, LLP Kinnate Biopharma Inc. Call Options Transaction History

Susquehanna International Group, LLP

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 07, 2024	BUY	$2.24 - $2.66 $55,328 - $65,702	24,700 New	24,700 $65,000
Q1 2023 May 16, 2023	BUY	$3.46 - $7.98 $131,826 - $304,038	38,100 New	38,100 $238,000
Q3 2022 Nov 14, 2022	SELL	$9.86 - $15.76 $11,832 - $18,912	-1,200 Reduced 4.86%	23,500 $281,000
Q2 2022 Aug 15, 2022	BUY	$7.43 - $13.0 $32,692 - $57,200	4,400 Added 21.67%	24,700 $311,000
Q1 2022 May 16, 2022	BUY	$7.73 - $17.99 $156,919 - $365,196	20,300 New	20,300 $229,000

292K

Ticker KNTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,145,600
Description
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.